期刊文献+

Biomarkers for pancreatic cancer:Recent achievements in proteomics and genomics through classical and multivariate statistical methods 被引量:5

Biomarkers for pancreatic cancer:Recent achievements in proteomics and genomics through classical and multivariate statistical methods
下载PDF
导出
摘要 Pancreatic cancer(PC) is one of the most aggressive and lethal neoplastic diseases. A valid alternative to the usual invasive diagnostic tools would certainly be the determination of biomarkers in peripheral fluids to provide less invasive tools for early diagnosis. Nowadays, biomarkers are generally investigated mainly in peripheral blood and tissues through high-throughput omics techniques comparing control vs pathological samples. The results can be evaluated by two main strategies:(1) classical methods in which the identification of significant biomarkers is accomplished by monovariate statistical tests where each biomarker is considered as independent from the others; and(2) multivariate methods, taking into consideration the correlations existing among the biomarkers themselves. This last approach is very powerful since it allows the identification of pools of biomarkers with diagnostic and prognostic performances which are superior to single markers in terms of sensitivity, specificity and robustness. Multivariate techniques are usually applied with variable selection procedures to provide a restricted set of biomarkers with the best predictive ability; however, standard selection methods are usually aimed at the identification of the smallest set of variables with the best predictive ability and exhaustivity is usually neglected. The exhaustive search for biomarkers is instead an important alternative to standard variable selection since it can provide information about the etiology of the pathology by producing a comprehensive set of markers. In this review, the most recent applications of the omics techniques(proteomics, genomics and metabolomics) to the identification of exploratory biomarkers for PC will be presented with particular regard to the statistical methods adopted for their identification. The basic theory related to classical and multivariate methods for identification of biomarkers is presented and then, the most recent applications in this field are discussed. Pancreatic cancer (PC) is one of the most aggressive and lethal neoplastic diseases. A valid alternative to the usual invasive diagnostic tools would certainly be the determination of biomarkers in peripheral fluids to provide less invasive tools for early diagnosis. Nowadays, biomarkers are generally investigated mainly in peripheral blood and tissues through high-throughput omics techniques comparing control vs pathological samples. The results can be evaluated by two main strategies: (1) classical methods in which the identification of significant biomarkers is accomplished by monovariate statistical tests where each biomarker is considered as independent from the others; and (2) multivariate methods, taking into consideration the correlations existing among the biomarkers themselves. This last approach is very powerful since it allows the identification of pools of biomarkers with diagnostic and prognostic performances which are superior to single markers in terms of sensitivity, specificity and robustness. Multivariate techniques are usually applied with variable selection procedures to provide a restricted set of biomarkers with the best predictive ability; however, standard selection methods are usually aimed at the identification of the smallest set of variables with the best predictive ability and exhaustivity is usually neglected. The exhaustive search for biomarkers is instead an important alternative to standard variable selection since it can provide information about the etiology of the pathology by producing a comprehensive set of markers. In this review, the most recent applications of the omics techniques (proteomics, genomics and metabolomics) to the identification of exploratory biomarkers for PC will be presented with particular regard to the statistical methods adopted for their identification. The basic theory related to classical and multivariate methods for identification of biomarkers is presented and then, the most recent applications in this field are discussed.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第37期13325-13342,共18页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献10

  • 1Ian McCaffery,Yanyan Tudor,Hongjie Deng,Rui Tang,Samuel Suzuki,Sunita Badola,Hedy L. Kindler,Charles S. Fuchs,Elwyn Loh,Scott D. Patterson,Li Chen,Jennifer L. Gansert.Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor[J].Clinical Cancer Research.2013(15)
  • 2Da-Wei Chen,Yao-Fu Fan,Jiang Li,Xiao-Xiao Jiang.MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma[J].Tumor Biology.2013(3)
  • 3Takeshi Ogura,Kenji Yamao,Kazuo Hara,Nobumasa Mizuno,Susumu Hijioka,Hiroshi Imaoka,Akira Sawaki,Yasumasa Niwa,Masahiro Tajika,Shinya Kondo,Tsutomu Tanaka,Yasuhiro Shimizu,Vikram Bhatia,Kazuhide Higuchi,Waki Hosoda,Yasushi Yatabe.Prognostic value of K - ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer[J].Journal of Gastroenterology.2013(5)
  • 4Michael Haas,Volker Heinemann,Frank Kullmann,Rüdiger P. Laubender,Christina Klose,Christiane J. Bruns,Stefan Holdenrieder,Dominik P. Modest,Christoph Schulz,Stefan Boeck.Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy[J].Journal of Cancer Research and Clinical Oncology.2013(4)
  • 5Claus Sch?fer,Hendrik Seeliger,Dominik C. Bader,Gerald Assmann,Denise Buchner,Yang Guo,Andreas Ziesch,Andreas Palagyi,Stephanie Ochs,Rüdiger P. Laubender,Andreas Jung,Enrico N. De Toni,Thomas Kirchner,Burkhard G?ke,Christiane Bruns,Eike Gallmeier.Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma[J].Journal of Cellular and Molecular Medicine.2012(8)
  • 6Rita Polati,Michele Menini,Elisa Robotti,Renato Millioni,Emilio Marengo,Enrico Novelli,Stefania Balzan,Daniela Cecconi.Proteomic changes involved in tenderization of bovine Longissimus dorsi muscle during prolonged ageing[J]. Food Chemistry . 2012 (3)
  • 7Joao A. Paulo,Raul Urrutia,Peter A. Banks,Darwin L. Conwell,Hanno Steen.Proteomic analysis of a rat pancreatic stellate cell line using liquid chromatography tandem mass spectrometry (LC-MS/MS)[J].Journal of Proteomics.2011(2)
  • 8Prabhjit Kaur,Kathryn Sheikh,Alexander Kirilyuk,Ksenia Kirilyuk,Rajbir Singh,Habtom W. Ressom,Amrita K. Cheema.Metabolomic profiling for biomarker discovery in pancreatic cancer[J].International Journal of Mass Spectrometry.2011
  • 9Kimberly Q. McKinney,Yong-Yook Lee,Hyun-Su Choi,Gale Groseclose,David A. Iannitti,John B. Martinie,Mark W. Russo,Deborah H. Lundgren,David K. Han,Herbert L. Bonkovsky,Sun-Il Hwang.Discovery of putative pancreatic cancer biomarkers using subcellular proteomics[J].Journal of Proteomics.2010(1)
  • 10David L. Morse,Yoga Balagurunathan,Galen Hostetter,Maria Trissal,Narges K. Tafreshi,Nancy Burke,Mark Lloyd,Steven Enkemann,Domenico Coppola,Victor J. Hruby,Robert J. Gillies,Haiyong Han.Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray[J].Biochemical Pharmacology.2010(5)

共引文献7

同被引文献19

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部